Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/11/2020 11:07 PDT] Advaxis, Inc. (NASDAQ:ADXS), Up By 100.00% ($0.72) From $0.720 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/29/2020 07:57 PDT] sector Stocks Expected To Be Up After Top Correlated Stocks Fire Buy Signals.
• [04/08/2020 12:23 PDT] Advaxis, Inc. (NASDAQ:ADXS), Up By 100.00% ($0.58) From $0.580 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/08/2020 11:07 PDT] Advaxis, Inc. (NASDAQ:ADXS), Up By 100.00% ($0.56) From $0.555 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions